Algernon Pharmaceuticals Inc. highlighted an independent research review published in the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19. The Review focuses on the sigma-1 receptor in the endoplasmic reticulum, a network of membranes inside a cell through which proteins and other molecules move, and its important role in SARS-CoV-2 replication in cells. The Review proposes the repurposing of traditional central nervous system drugs that have a high affinity at the sigma-1 receptor, naming Ifenprodil as a potential treatment of SARS-CoV-2-infected patients. The Review can be found here at Sigma-1 Receptor Research and was authored by Kenji Hashimoto and supported in part by the Japan Society for the Promotion of Science and the Japan Agency for Medical Research and Development. The company recently announced that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, completed treatment as well as the required two-week follow up. The Company is projecting the final data set will be available before the end of February 2021. The company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.